Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model

International Journal of Antimicrobial Agents

Volumn 9, Issue 2, 1997, Pages 131-135

  Brody, Suzanne R ^a   Aweeka, Francesca T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug interaction; Intracellular; Stavudine; Zidovudine

Indexed keywords

STAVUDINE; ZIDOVUDINE;

ARTICLE; BLOOD; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; INTRACELLULAR FLUID; MONONUCLEAR CELL; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0030817050     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00041-1     Document Type: Article

References (14)

1. International AIDS Society, USA. Antiretroviral therapy for HIV Infection in 1996; recommendations of an international panel. J Am Med Assoc 1996;276:146-154.
2. Furman PA, Fyfe JA, St. Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-7.
3. Tornevik Y, Jacobsson B, Britton S, Eriksson S. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1991;7:751-9.
4. Sommadossi J. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′,3′-dideoxynucleoside analogues. J Infect Dis 1995;171 Suppl 2:888-92.
5. Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989;264:6127-33.
6. Pollard RB. D4T nucleoside combinations for HIV. Antiviral Res 1996;29:101-4.
7. Merrill DP, Moonis M, Chou T-C, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996;173:355-64.
8. Zhu Q-Y, Scarborough A, Polsky B, Chou T-C. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses 1996;12:507-17.
9. Peter K, Lalezari JP, Gambertoglio JG. Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method. J Pharm Biomed Anal 1996;14:491-9.
10. Gibaldi M. Noncompartmental pharmacokinetics. In: Biopharmaceutics and clinical pharmacokinetics, 3rd ed. Philadelphia: Lea and Febiger, 1984:1728.
11. Hoggard P, Khoo S, Barry M. Back D. Intracellular metabolism of zidovudine and stavudine in combination. J Infect Dis 1996;174:671-2.
12. Ahluwalia GS, Gao W, Mitsuya H, Johns DG. 2′3′-didehydro-3′deoxythymidine: Regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Mol Pharmacol 1996;50:160-5.
13. Ho H, Hitchcock MJM. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989;33:844-9.
14. Peter K, Gambertoglio JG. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. Clin Pharmacol Ther 1996;60:168-76.